Pancreatic Cancer Vaccine Triggers Immune Response

Patients with KRAS-mutated pancreatic cancer saw strong immune activity, but the vaccine did not significantly extend disease-free survival in this trial.

Updated on Nov. 3, 2026 in Cancer

Isometric editorial illustration of a single upright glass vial of amber liquid beside clustered cell forms on a cream background. — A phase 2 trial of the experimental pancreatic cancer vaccine camupepimut triggered strong immune responses but did not significantly extend disease-free survival. AI Illustration. Upload story photo >

Live Poll

Should the government increase funding for experimental cancer research?

A phase 2 clinical trial found that an experimental personalized vaccine, camupepimut, did not significantly extend disease-free survival in patients with KRAS-mutated pancreatic cancer after surgery and chemotherapy. The vaccine did produce strong immune responses, and researchers plan further development.

Why it matters

Pancreatic cancer is among the hardest cancers to treat, and recurrence after surgery is a major concern for patients. The findings show that a vaccine can reliably trigger immune responses against cancer mutations, yet that immune activity did not translate into a clear survival benefit in this trial, which is why researchers are refining the approach rather than declaring success.

This phase 2 randomized trial enrolled 144 patients with KRAS-mutated pancreatic cancer who had no detectable signs of cancer after surgery and chemotherapy. Vaccinated patients (96) had a slightly longer average disease-free survival than observed patients (48), but the difference was not statistically significant.

The players

Mayo Clinic

A major academic medical center known for cancer research and clinical trials, where the lead researchers of this study are based.

The details

The vaccine delivers its ingredients to the lymph nodes by attaching to a fatty molecule that binds the blood protein albumin. Nearly 99 percent of vaccinated patients developed increased T-cell responses against the mutated KRAS protein. Patients with no detectable circulating tumor DNA at the start of the study stayed cancer-free longer when they received the vaccine.

Over 46 weeks after the study began, 95.5 percent of patients showed detectable T-cell responses to KRAS mutations.

Health Landscape

Personalized vaccines targeting tumor mutations are part of a growing pipeline of approaches for pancreatic cancer, a disease whose global case count rose from roughly 196,000 new cases in 1990 to about 510,000 in 2022. This trial adds evidence that immune activation can be achieved, while showing that translating it into survival gains remains an open challenge.

If you or a family member has been treated for pancreatic cancer, this trial is a reminder that experimental vaccines remain investigational and are not yet a proven way to prevent recurrence. It is worth discussing with your oncologist whether any ongoing clinical trials might be appropriate.

The takeaway

Personalized vaccines can reliably provoke immune responses against tumor mutations, but a strong immune response alone has not yet shown a clear survival benefit in pancreatic cancer. Readers facing a recurrence risk should raise current trial options with their oncologist.